Immunogenicity and safety of primary three-dose series with diphtheria, tetanus and pertussis (acellular, three components) combined vaccine, adsorbed in 3 months infants - Report - MDSpire
Advertisement
Immunogenicity and safety of primary three-dose series with diphtheria, tetanus and pertussis (acellular, three components) combined vaccine, adsorbed in 3 months infants
Clinical Report: Evaluation of Safety and Immune Response in Infants Receiving a Three-Dose Series of a Combined Diphtheria, Tetanus, and Acellular Pertussis Vaccine
Overview
This study evaluated the safety and immunogenicity of a novel diphtheria, tetanus, and pertussis (acellular, three components) combined vaccine (DTcP) in infants. The DTcP vaccine demonstrated a superior immune response compared to the co-purified DTaP vaccine, with a comparable safety profile.
Background
Pertussis remains a significant cause of morbidity and mortality in infants globally, with a concerning resurgence in cases noted in China. The transition from whole-cell to acellular pertussis vaccines in immunization programs has raised questions about long-term efficacy and safety. Understanding the immunogenicity and safety of new vaccine formulations is critical for optimizing immunization strategies.
Data Highlights
Vaccine
Adverse Reactions
Anti-PT GMC
Anti-FHA GMC
Seroconversion Rate for Anti-FHA
DTcP
17.99%
85.10
108.28
98.16%
Co-purified DTaP
18.08%
49.86
10.69
14.29%
DTaP-IPV-Hib
21.96%
74.25
N/A
N/A
Key Findings
The DTcP vaccine showed lower incidences of overall adverse reactions compared to DTaP-IPV-Hib (17.99% vs. 21.96%).
DTcP demonstrated non-inferiority and superiority over co-purified DTaP for anti-PT and anti-FHA immunogenicity.
The seroconversion rate for anti-FHA was significantly higher in the DTcP group (98.16%) compared to the co-purified DTaP (14.29%).
Anti-PT GMC was significantly higher in the DTcP group (85.10) compared to the co-purified DTaP (49.86) and DTaP-IPV-Hib (74.25).
DTcP vaccine utilizes a novel gene expression-based platform for antigen purification and detoxification.
Clinical Implications
The findings suggest that the DTcP vaccine may provide a more robust immune response to key pertussis antigens while maintaining a favorable safety profile. This could inform future immunization strategies in regions experiencing pertussis resurgence.
Conclusion
The DTcP vaccine offers a promising alternative to the co-purified DTaP vaccine, with enhanced immunogenicity and a comparable safety profile, supporting its potential use in immunization programs.
A large Epic Cosmos analysis linked vaginal estrogen prescribing with lower rates of sepsis, hospital admission, and death following recurrent urinary tract infection, but researchers cautioned that prescribing may also mark broader differences in care.
